Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
about
A Review of Patient Preferences for Osteoporosis Drug TreatmentCompliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISACompliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment.Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation settingEfficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trialsPersistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional studyClinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.Managing bone health with zoledronic acid: a review of randomized clinical study results.Adaptation to microgravity, deconditioning, and countermeasures.Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™.Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates--the VIVA II study.Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene.Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.Osteoporosis Patient Treatment Satisfaction Questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study.Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study.
P2860
Q26796811-C06BAFCB-65BD-4F6F-878B-BFBD8F800D2BQ30988951-F442DF65-0C96-40AE-9855-B2DB5596AFDCQ33667473-61CEBC27-92CD-4C40-AD2F-6AF895C83516Q34041189-521E0FA3-7ED6-4BE1-A508-41A3433BAE59Q34055595-71161E64-656D-42E1-B371-5111451F2315Q35331699-173E9628-BB53-48CA-BA3D-DF9FA673F5D2Q36073613-DBDBF18E-B831-4BFB-9F93-032D0BE1968BQ36162247-31769576-AE0B-4377-81FE-2B6A09B3C424Q36897441-A0777E76-7F3C-49A3-BE8F-85058F5BA383Q37402282-3F94DFB9-352F-443E-8F8B-5487C93FC5E2Q37768696-CA203C49-39D3-47E5-ABB5-7FC03381EF00Q37823605-089D3ABC-9D28-4604-A85C-EAC1477DB0A1Q39045178-038D4A6A-9BF8-477A-AEF6-F1E7E76F19D0Q41704724-E0A0E1EC-3651-4A48-B61F-2E5F468CD973Q42674633-39A9AA1F-A4A7-4F79-AE3A-171575B6FB1CQ42877288-DB9E49C1-996C-4451-B11D-4658CBCCEE41Q44892769-C4258B39-AFBE-40AF-BBAE-E105F627EC77Q46025463-36D91E9F-C7CB-4B1A-A6A3-4D2616841DA8Q48256965-24FD1EA7-5B69-41A6-AFAD-438FA7CAE379Q48545123-73F8C72B-8175-4A21-AC8F-5FB244D78317Q48573732-2A2283B3-301D-46AB-A91D-AC99EBE7FF82Q48581497-8F8719B4-386C-4987-86CD-D4AF128D46F8Q53398650-57279981-FD5C-40C2-A49A-9108DF5F014DQ54615209-35513B86-B78D-4417-AF8B-63B9986F9EA8
P2860
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Treatment preference for month ...... d, crossover study (BALTO II).
@en
Treatment preference for month ...... d, crossover study (BALTO II).
@nl
type
label
Treatment preference for month ...... d, crossover study (BALTO II).
@en
Treatment preference for month ...... d, crossover study (BALTO II).
@nl
prefLabel
Treatment preference for month ...... d, crossover study (BALTO II).
@en
Treatment preference for month ...... d, crossover study (BALTO II).
@nl
P2093
P1433
P1476
Treatment preference for month ...... d, crossover study (BALTO II).
@en
P2093
Angelo Licata
Daiva Masanauskaite
Elizabeth Barrett-Connor
Helmut Minne
Michael Pfeifer
Patrice Fardellone
Peyman Hadji
Pierre Bourgeois
Vipul Devas
P304
P356
10.1016/J.JBSPIN.2007.07.011
P577
2007-10-22T00:00:00Z